Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Corvert Generic Name & Formulations
Legal Class
Rx
General Description
Ibutilide fumarate 0.1mg/mL; soln for IV infusion.
Pharmacological Class
Class III antiarrhythmic.
How Supplied
Single-dose vial (10mL)—1
Manufacturer
Corvert Indications
Indications
Rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Corvert Dosage and Administration
Adult
Give by IV infusion over 10 minutes. ≥18yrs: (≥60kg) initially 1mg; (<60kg) initially 0.01mg/kg. If no response, may repeat second 10-minute infusion of equal strength given 10 minutes after first infusion. Discontinue infusion as soon as the presenting arrhythmia has terminated, or if sustained/nonsustained ventricular tachycardia or marked QT prolongation occurs.
Children
<18yrs: not recommended.
Corvert Contraindications
Not Applicable
Corvert Boxed Warnings
Not Applicable
Corvert Warnings/Precautions
Warnings/Precautions
Risk of fatal arrhythmias (eg, sustained polymorphic ventricular tachycardia, usually associated with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation may occur. Be experienced with the treatment and monitoring of life-threatening arrhythmias before administering. Have cardiac monitoring equipment and proper medication available. Correct hypokalemia and hypomagnesemia before starting. Monitor ECG continuously for at least 4 hours post infusion or until QTC returned to baseline. Proarrhythmia conditions (eg, ventricular arrhythmias, atrial flutter or fibrillation, QTC intervals >440 msec, hypokalemia, history of CHF, low left ventricular ejection fraction). Previous polymorphic ventricular tachycardia: not recommended. Renal or hepatic dysfunction (monitor). Pregnancy (Cat.C). Nursing mothers: not recommended.
Corvert Pharmacokinetics
See Literature
Corvert Interactions
Interactions
Class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide) or other Class III drugs (eg, amiodarone, sotalol): do not give concomitantly or within 4 hours post-infusion. QT prolongation with phenothiazines, tricyclic and tetracyclic antidepressants, H1 receptor antagonists. Caution with digoxin.
Corvert Adverse Reactions
Adverse Reactions
Ventricular extrasystoles, sustained or nonsustained polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, headache, hypo- or hypertension, tachycardia, bundle branch block, AV block, nausea, QT segment prolonged, bradycardia.
Corvert Clinical Trials
See Literature
Corvert Note
Not Applicable
Corvert Patient Counseling
See Literature
